Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem Biosciences (OTCID: EVFM) reported significant success from its August 2025 "Say Vagina" campaign, designed to normalize clinical anatomical language. The campaign generated over 2.5 million views across social media platforms and drove a 130% increase in traffic to PHEXXI.com, the company's hormone-free contraceptive product website.
Key achievements include PHEXXI becoming the #1 most followed contraceptive brand among healthcare providers, and CEO Saundra Pelletier's Instagram reach growing by 400%. The company plans to launch SayVaginaStore.com in September, with all proceeds from campaign merchandise being donated to selected sexual and reproductive health charities.
Evofem Biosciences (OTCID: EVFM) ha annunciato l'enorme successo della campagna "Say Vagina" di agosto 2025, pensata per normalizzare il linguaggio anatomico clinico. La campagna ha registrato oltre 2,5 milioni di visualizzazioni sui social media e ha generato un aumento del traffico verso PHEXXI.com, il sito del contraccettivo senza ormoni dell'azienda, pari al 130%.
Tra i risultati principali, PHEXXI è diventato il marchio contraccettivo più seguito tra gli operatori sanitari e la portata Instagram dell'amministratrice delegata Saundra Pelletier è cresciuta del 400%. La società prevede di lanciare SayVaginaStore.com a settembre: tutti i proventi dei gadget della campagna saranno devoluti a organizzazioni selezionate per la salute sessuale e riproduttiva.
Evofem Biosciences (OTCID: EVFM) informó del notable éxito de su campaña "Say Vagina" de agosto de 2025, creada para normalizar el lenguaje anatómico clínico. La campaña obtuvo más de 2,5 millones de visualizaciones en redes sociales y provocó un aumento del 130% en el tráfico a PHEXXI.com, el sitio del anticonceptivo sin hormonas de la compañía.
Entre los logros principales figura que PHEXXI se convirtió en la marca anticonceptiva con más seguidores entre profesionales sanitarios, y que el alcance en Instagram de la consejera delegada Saundra Pelletier creció un 400%. La empresa prepara el lanzamiento de SayVaginaStore.com en septiembre, y todos los beneficios de la mercancía de la campaña se donarán a organizaciones seleccionadas de salud sexual y reproductiva.
Evofem Biosciences (OTCID: EVFM)는 임상 해부학 용어를 정상화하기 위해 2025년 8월 진행한 "Say Vagina" 캠페인이 큰 성공을 거뒀다고 발표했습니다. 이 캠페인은 소셜 미디어에서 250만 회 이상의 조회수를 기록했으며, 회사의 무호르몬 피임제 웹사이트인 PHEXXI.com으로의 트래픽을 130% 증가시켰습니다.
주요 성과로는 PHEXXI가 의료진 사이에서 가장 팔로우가 많은 피임 브랜드가 되었고, CEO인 Saundra Pelletier의 인스타그램 도달률이 400% 증가한 점이 있습니다. 회사는 9월에 SayVaginaStore.com을 출시할 예정이며, 캠페인 굿즈의 수익 전액을 선정된 성 및 생식 건강 관련 자선단체에 기부할 계획입니다.
Evofem Biosciences (OTCID: EVFM) a annoncé le succès notable de sa campagne « Say Vagina » d'août 2025, visant à normaliser le vocabulaire anatomique clinique. La campagne a généré plus de 2,5 millions de vues sur les réseaux sociaux et a entraîné une hausse de 130% du trafic vers PHEXXI.com, le site du contraceptif sans hormones de la société.
Parmi les réalisations clés, PHEXXI est devenu la marque contraceptive la plus suivie auprès des professionnels de santé, et la portée Instagram de la PDG Saundra Pelletier a augmenté de 400%. La société prévoit de lancer SayVaginaStore.com en septembre ; tous les bénéfices des produits de la campagne seront reversés à des associations choisies œuvrant pour la santé sexuelle et reproductive.
Evofem Biosciences (OTCID: EVFM) meldete großen Erfolg mit seiner August-Kampagne 2025 "Say Vagina", die darauf abzielte, klinische anatomische Begriffe zu normalisieren. Die Kampagne erzielte über 2,5 Millionen Aufrufe in den sozialen Medien und führte zu einem 130%igen Anstieg des Traffics auf PHEXXI.com, der Website des hormonfreien Verhütungsmittels des Unternehmens.
Zu den wichtigsten Erfolgen zählt, dass PHEXXI die #1 der meistgefolgten Verhütungsmarken unter medizinischem Fachpersonal wurde und die Instagram-Reichweite der CEO Saundra Pelletier um 400% zulegte. Das Unternehmen plant im September den Start von SayVaginaStore.com; alle Erlöse aus der Kampagnenware werden an ausgewählte Organisationen für sexuelle und reproduktive Gesundheit gespendet.
- Campaign generated over 2.5 million social media views
- 130% increase in traffic to PHEXXI.com during campaign period
- PHEXXI became #1 most followed contraceptive brand among healthcare providers
- CEO's Instagram reach grew 400%
- New e-commerce initiative with charitable focus launching
- None.
Insights
Evofem's provocative "Say Vagina" campaign drove 130% website traffic increase and significant brand awareness, potentially enhancing PHEXXI's market position.
Evofem's just-concluded "Say Vagina" campaign demonstrates a remarkably effective digital marketing strategy for their hormone-free contraceptive PHEXXI. The 130% increase in website traffic represents a substantial conversion metric that typically correlates with increased prescription inquiries and potential sales growth. Most pharmaceutical companies struggle to achieve double-digit traffic increases from digital campaigns, making this result particularly notable.
The achievement of becoming the #1 most followed contraceptive brand among healthcare providers is especially significant. Provider engagement is a critical metric in pharmaceutical marketing since prescriber awareness directly influences prescription rates. This standing suggests Evofem has successfully penetrated the medical community, which typically requires substantial educational outreach.
The 2.5 million views across social platforms indicates exceptional reach for a pharmaceutical campaign, especially considering the regulatory constraints that typically limit healthcare marketing. By focusing on anatomical language normalization rather than direct product promotion, Evofem cleverly navigated potential regulatory hurdles while still driving substantial brand awareness.
The planned merchandise store with charitable donation component represents a strategic extension that could maintain momentum beyond the initial campaign while building goodwill. This approach aligns with contemporary marketing practices that emphasize corporate social responsibility, which can strengthen brand loyalty among both patients and providers.
Overall, these metrics suggest Evofem has effectively differentiated PHEXXI in the competitive contraceptive market through provocative but purposeful marketing that resonates with both consumers and healthcare professionals.
--
-- PHEXXI® is #1 most followed contraceptive brand on social media by healthcare providers --
This edgy and provocative campaign tapped into areas of urgent educational need and partnered with leaders across multiple fields.
Tangible Campaign Impact
- More than 2.5 million views were generated across social media platforms.
130% increase in traffic to phexxi.com, the website for Evofem's hormone-free prescription. contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate), during Say Vagina Month.- PHEXXI® is now the most followed contraceptive brand among healthcare providers.
- Marked increase in patients, providers, and educators reaching out to learn more about Evofem, Saundra Pelletier and PHEXXI®.
- Saundra Pelletier's Instagram reach grew over
400% , the majority from non-followers.
"The Say Vagina campaign aimed to transform shame into empowerment through language normalization and created space for open dialogue about women's bodies and health," said Saundra Pelletier, CEO of Evofem Biosciences. "Throughout Say Vagina Month, voices from across the globe came together through videos, stories, and shared experiences. Every contribution helped dismantle stigma and replace silence with strength. This campaign proves that when we normalize the language of our bodies, we normalize respect, understanding, and choice. We are deeply grateful to everyone who participated in making Say Vagina Month a movement that continues to ripple far beyond its 31 days."
What's Next
To ensure this momentum does not end with one month, Evofem plans to launch SayVaginaStore.com in September. The store will offer empowerment merchandise, with
About Evofem Biosciences
Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.
PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information.
SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.
PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
Additional Information
Evofem filed a Definitive Proxy on September 8, 2025, for the Special Meeting of Stockholders to be held on Friday, September 26, 2025, at which stockholders of record will be asked to consider and vote on a proposal to approve the transactions contemplated under the Merger Agreement between the Company, Aditxt, Inc. (NASDAQ: ADTX) and Adifem, Inc., a wholly owned subsidiary of Aditxt. Pursuant to the Merger Agreement, Adifem will merge with and into the Company, with Evofem surviving as a wholly owned subsidiary of Aditxt. The closing of the transactions contemplated by the Merger Agreement is subject to conditions including, but not limited to, approval of the transactions by a majority of the combined voting power of Evofem's Series E-1, Series G-1 and common stock, voting together as a single class, the affirmative vote of holders of a majority of each of the Series E-1 and G-1, Aditxt raising sufficient capital to fund its closing obligations, and other customary closing conditions.
For additional information regarding the proposals to be acted upon at the upcoming Special Meeting, please refer to Evofem's Definitive Proxy, which is available free of charge through the SEC's website at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001618835/000164117225026774/formdefm14a.htm
BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY, AS IT CONTAINS IMPORTANT INFORMATION REGARDING THE MATTERS TO BE CONSIDERED AT THE SPECIAL MEETING. STOCKHOLDERS WITH QUESTIONS ARE ENCOURAGED TO CONTACT THE COMPANY AT IR@EVOFEM.COM
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to the timing of the launch of sayvaginastore.com. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
Connect With Us
Media
Media@evofem.com
Investors and Potential Partners
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
Join the Dialogue
TikTok | |
X | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofems-say-vagina-campaign-generates-more-than-2-5-million-views-across-social-media-platforms-302553932.html
SOURCE Evofem Biosciences, Inc.
FAQ
What were the results of Evofem's (EVFM) 'Say Vagina' campaign in August 2025?
How did the 'Say Vagina' campaign affect PHEXXI's market presence?
What is Evofem's (EVFM) plan following the 'Say Vagina' campaign success?
How did the campaign impact Evofem's social media presence?
